TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA DRY EYE SYNDROME MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 NORTH AMERICA DRY EYE SYNDROME MARKET: GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 DBMR VENDOR SHARE ANALYSIS
2.9 MULTIVARIATE MODELING
2.10 PRODUCTS LIFELINE CURVE
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.1.1 INCREASING PREVALENCE OF DRY EYE DISEASES
3.1.2 CHANGING GEOGRAPHICAL TRENDS TO DRIVE THE MARKET
3.1.3 INCREASING AWARENESS ABOUT DIAGNOSIS AND TREATMENT OF THE DISEASE
3.1.4 RISING GERIATRIC POPULATION ACROSS THE WORLD
3.1.5 INCREASE IN LASIK SURGERY AND USAGE OF CONTACT LENSES
3.2 RESTRAINTS
3.2.1 STRINGENT REGULATORY PROCESS
3.2.2 UNMET MEDICAL NEEDS
3.3 OPPORTUNITIES
3.3.1 EMERGING MARKET PRESENTS SIGNIFICANT OPPORTUNITIES
3.3.2 DEVELOPMENT OF NOVEL TECHNOLOGIES
3.4 CHALLENGE
3.4.1 INCREASING NUMBER OF PLAYERS
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 PIPELINE ANALYSIS
6.1 OVERVIEW
6.2 MARKETED DRUGS
6.3 APPROVED/FILED DRUGS
6.4 PHASE III TRIAL CANDIDATES
6.5 PHASE II TRIAL CANDIDATES
6.6 PHASE I TRIAL CANDIDATES
6.7 OTHERS
7 NORTH AMERICA DRY EYE SYNDROME MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 TEAR STIMULATORS
7.2.1 PILOCARPINE
7.2.2 CYCLOSPORINE
7.2.3 LIFITEGRAST
7.3 ARTIFICIAL TEARS
7.3.1 SECRETAGOGUE
7.3.2 OTHERS
8 NORTH AMERICA DRY EYE SYNDROME MARKET, BY DOSAGE TYPE
8.1 OVERVIEW
8.2 LIQUID
8.2.1 SOLUTIONS
8.2.2 EMULSIONS
8.2.3 SUSPENSIONS
8.3 SEMI-SOLID
8.3.1 GEL
8.3.2 OINTMENT
8.4 OTHERS
9 NORTH AMERICA DRY EYE SYNDROME MARKET, BY DRUG CLASS
9.1 OVERVIEW
9.2 ANTI-INFLAMMATORY
9.3 LUBRICATING AGENT
9.4 ANTI-INFECTIVE
9.5 ANTI-ALLERGIC
9.6 CHOLINERGIC
9.7 OTHERS
10 NORTH AMERICA DRY EYE SYNDROME MARKET, BY DOSE
10.1 OVERVIEW
10.2 MULTI DOSE
10.3 UNIT DOSE
11 NORTH AMERICA DRY EYE SYNDROME MARKET, BY MEDICATION TYPE
11.1 OVERVIEW
11.2 PRESCRIPTION (RX) DRUGS
11.3 OVER THE COUNTER (OTC) DRUGS
12 NORTH AMERICA DRY EYE SYNDROME MARKET, BY CONTAINER TYPE
12.1 OVERVIEW
12.2 UNIT DOSE VIALS
12.3 BOTTLES
12.4 TUBES
13 NORTH AMERICA DRY EYE SYNDROME MARKET, BY PACKAGING TYPE
13.1 OVERVIEW
13.2 PLASTIC
13.3 GLASS
13.4 ALUMINIUM
14 NORTH AMERICA DRY EYE SYNDROME MARKET, BY TYPE
14.1 OVERVIEW
14.2 GENERIC DRUG
14.3 BRANDED
14.3.1 RESTASIS
14.3.2 XIIDRA
14.3.3 REFRESH
14.3.4 SYSTANE
14.3.5 TEARS NATURALE
14.3.6 IKERVIS
14.3.7 DIQUAS
14.3.8 OTHERS
15 NORTH AMERICA DRY EYE SYNDROME MARKET, BY END USER
15.1 OVERVIEW
15.2 HOME HEALTHCARE
15.3 HOSPITALS
15.4 CLINICS
15.5 OTHERS
16 NORTH AMERICA DRY EYE SYNDROME MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACIES
16.3 RETAIL PHARMACIES
16.4 ONLINE PHARMACIES
16.5 OTHERS
17 NORTH AMERICA DRY EYE SYNDROME MARKET BY GEOGRAPHY
17.1 NORTH AMERICA
17.1.1 U.S.
17.1.2 CANADA
17.1.3 MEXICO
18 NORTH AMERICA DRY EYE SYNDROME MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
19 SWOT ANALYSIS
19.1 DATA BRIDGE MARKET RESEARCH ANALYSIS-
20 COMPANY PROFILE
20.1 ALLERGAN
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 GEOGRAPHICAL PRESENCE
20.1.5 PRODUCT PORTFOLIO
20.1.6 RECENT DEVELOPMENTS
?
20.2 NOVARTIS AG
20.2.1 COMPANY OVERVIEW
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 GEOGRAPHICAL PRESENCE
20.2.5 PRODUCT PORTFOLIO
20.2.6 RECENT DEVELOPMENT
20.3 BAUSCH & LOMB INCORPORATED.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 GEOGRAPHICAL PRESENCE
20.3.5 PRODUCT PORTFOLIO
20.3.6 RECENT DEVELOPMENT
20.4 SANTEN PHARMACEUTICAL CO., LTD.
20.4.1 COMPANY OVERVIEW
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 GEOGRAPHICAL PRESENCE
20.4.5 PRODUCT PORTFOLIO
20.4.6 RECENT DEVELOPMENT
20.5 JOHNSON & JOHNSON SERVICES, INC.
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 GEOGRAPHICAL PRESENCE
20.5.5 PRODUCT PORTFOLIO
20.5.6 RECENT DEVELOPMENTS
20.6 AKORN, INCORPORATED
20.6.1 COMPANY OVERVIEW
20.6.2 REVENUE ANALYSIS
20.6.3 GEOGRAPHICAL PRESENCE
20.6.4 PRODUCT PORTFOLIO
20.6.5 RECENT DEVELOPMENT
20.7 ALCON INC
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE ANALYSIS
20.7.3 GEOGRAPHICAL PRESENCE
20.7.4 PRODUCT PORTFOLIO
20.7.5 RECENT DEVELOPMENT
20.8 ALEMBIC PHARMACEUTICALS LIMITED
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 GEOGRAPHICAL PRESENCE
20.8.4 PRODUCT PORTFOLIO
20.8.5 RECENT DEVELOPMENTS
20.9 CARDINAL HEALTH
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 GEOGRAPHICAL PRESENCE
20.9.4 PRODUCT PORTFOLIO
20.9.5 RECENT DEVELOPMENTS
20.10 CIPLA INC
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 GEOGRAPHICAL PRESENCE
20.10.4 PRODUCT PORTFOLIO
20.10.5 RECENT DEVELOPMENTS
20.11 HORUS PHARMA
20.11.1 COMPANY OVERVIEW
20.11.2 GEOGRAPHICAL PRESENCE
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENT
20.12 HUBRX
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENTS
20.13 NOVALIQ GMBH
20.13.1 COMPANY OVERVIEW
20.13.2 GEOGRAPHICAL PRESENCE
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENT
20.14 PERRIGO COMPANY PLC
20.14.1 COMPANY SNAPSHOT
20.14.2 REVENUE ANALYSIS
20.14.3 GEOGRAPHICAL PRESENCE
20.14.4 PRODUCT PORTFOLIO
20.14.5 RECENT DEVELOPMENT
?
20.15 PRESTIGE CONSUMER HEALTHCARE, INC.
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENTS
20.16 ROHTO PHARMACEUTICAL CO., LTD.
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 GEOGRAPHICAL PRESENCE
20.16.4 PRODUCT PORTFOLIO
20.16.5 RECENT DEVELOPMENT
20.17 SENJU PHARMACEUTICAL CO. LTD.
20.17.1 COMPANY OVERVIEW
20.17.2 REVENUE ANALYSIS
20.17.3 GEOGRAPHICAL PRESENCE
20.17.4 PRODUCT PORTFOLIO
20.17.5 RECENT DEVELOPMENT
20.18 SUN PHARMACEUTICAL INDUSTRIES LTD.
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 GEOGRAPHICAL PRESENCE
20.18.4 PRODUCT PORTFOLIO
20.19 TEVA PHARMACEUTICAL INDUSTRIES LTD.
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 GEOGRAPHICAL PRESENCE
20.19.4 PRODUCT PORTFOLIO
20.19.5 RECENT DEVELOPMENT
20.19.6 RECENT DEVELOPMENTS
20.20 VISUFARMA
20.20.1 COMPANY OVERVIEW
20.20.2 GEOGRAPHICAL PRESENCE
20.20.3 PRODUCT PORTFOLIO
20.20.4 RECENT DEVELOPMENTS
21 REFERENCES
22 QUESTIONNAIRE
23 RELATED REPORTS